It is currently Tue May 24, 2016 4:41 pm

News News of ThisIsMS

Site map of ThisIsMS » Forum : ThisIsMS

Welcome to the world's leading forum on Multiple Sclerosis research, support, and knowledge. For over 10 years, This is MS has provided an unbiased community dedicated to Multiple Sclerosis patients, caregivers, and affected loved ones.

Fampridine results

Acorda Therapeutics Presents Data from its Phase 3 Study of Fampridine-SR in Multiple Sclerosis at the American Academy of Neurology Meeting

03 May 2007

Acorda Therapeutics, Inc.® today presented data from a Phase 3 clinical trial of Fampridine-SR in people with multiple sclerosis (MS) at the American Academy of Neurology meeting. Andrew Goodman, M.D., Director of the Multiple Sclerosis Center at the University of Rochester, presented top-line results on walking ability, leg strength, spasticity ...
Read more : Fampridine results | Views : 1708 | Replies : 0 | Forum : Drug Pipeline

MS simulator machine

<shortened url>
Just maybe of interest to some...
Read more : MS simulator machine | Views : 1585 | Replies : 3 | Forum : General Discussion

Th1 and Th2 responses: what are they?

This paper makes a few oft heard terms a little more understandable. I'm not certain of the exact date but I THINK it's from August 12, 2000.

Th1 and Th2 responses: what are they?

Abi Berger, science editor.


Cytokines are the hormonal messengers responsible for most of the biological effects in the immune system, such as cell mediated immunity and allergic type responses. Although they are numerous, cytokines can be functionally divided into ...
Read more : Th1 and Th2 responses: what are they? | Views : 3774 | Replies : 15 | Forum : General Discussion


Hello all.
I just joined today. I read back and found some things on SF1019. I found a lot of negative. As I read I understood that for the most part people who were commenting were frustrated because of lack of info. I have found that lack of knowledge regarding drug development and how the process works can be confusing and also make persons who are desperate for a cure find fault and look for ...
Read more : SF1019 | Views : 32255 | Replies : 42 | Forum : Aimspro

Campath Phase II results

Here are the Phase II Campath results. ... 050207.asp

I think they are impressive for those with RR MS (I'm biased because I've seen excellent results following my first infusion last November). And the impressive reduction in relapses is when compared with Rebif.

These sorts of treatments are riskier than the CRAB drugs, but the risks identified to date can be monitored and treated. And you don't see ...
Read more : Campath Phase II results | Views : 4346 | Replies : 17 | Forum : Drug Pipeline

Betaferon and delayed disability

Tuesday - May 1, 2007

First-of-its-Kind Data Show:
Immediate Treatment of Early MS Patients with Betaferon® Significantly Delayed Permanent Disability
Risk to confirmed EDSS progression reduced by 40 percent compared to delayed treatment

Berlin – Bayer Schering Pharma AG, Germany, announced today new data, which show that immediate initiation of Betaferon® (interferon beta-1b) treatment in patients with a first event suggestive of multiple sclerosis (MS) can significantly reduce the risk of permanent neurological impairment as ...
Read more : Betaferon and delayed disability | Views : 1308 | Replies : 0 | Forum : Drug Pipeline


Hi all,

It is possible to access the abstracts from the AAN meeting...Below is an example of one that I located (I'm not sure if it has been mentioned yet...if it has, I apologize ahead of time)...there are more articles on prospective meds as well as a host of other important info...

the link is ... 2007-05-01



Efficacy of Alemtuzumab in Treatment-Naive Relapsing-Remitting Multiple Sclerosis: ...
Read more : Alemtuzumab | Views : 1409 | Replies : 1 | Forum : Drug Pipeline

Laquinimod trial results

Don't appear that impressive - but it's oral.
Read more : Laquinimod trial results | Views : 1739 | Replies : 3 | Forum : Drug Pipeline

Rituxan® Phase II Data in Patients with RRMS

Rituxan® Phase II Data in Patients with Relapsing-Remitting Multiple Sclerosis Presented at the American Academy of Neurology

Rituxan® Significantly Reduced Signs Of Disease Activity As Measured By MRI and Relapse

BOSTON--(BUSINESS WIRE)--Genentech, Inc. (NYSE:DNA) and Biogen Idec, Inc. (Nasdaq:BIIB) announced that positive data from a Phase II clinical study of Rituxan® (rituximab) in patients with relapsing-remitting multiple sclerosis (RRMS) were presented today at the American Academy of Neurology annual meeting held in Boston. Rituxan is ...
Read more : Rituxan® Phase II Data in Patients with RRMS | Views : 1422 | Replies : 2 | Forum : Drug Pipeline


Login  •  Register


Total posts 232435 • Total topics 24847 • Total members 16005

Contact us | Terms of Service